Quantcast

Latest GlaxoSmithKline Stories

2014-05-15 08:31:23

CARLSBAD, Calif., May 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "We have had a very productive alliance with GlaxoSmithKline, from which we have advanced three antisense drugs in our...

2014-05-13 23:14:12

In its latest May 2014 survey, polyDNA found that 68% of respondents did not know if the same antiviral treatments are used against genital and oral herpes infections. polyDNA reviews the literature and recommends Gene-Eden-VIR and Novirin, natural antivirals, with a formula proven to reduce herpes symptoms. Rochester, NY (PRWEB) May 13, 2014 polyDNA’s latest survey found that 68% of respondents did not know if the same antiviral treatments are used against both genital and oral herpes...

2014-05-13 12:30:41

LONDON, May 13, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:China Pharmaceuticals and Healthcare Report Q2 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/china_pharmaceuticals_healthcare_report_q2_2013.html Includes 3 FREE quarterly updatesBMI View: Strong sales growth reported by multinational pharmaceutical firms in China over the courseof 2013 is directly in line with our longtermoptimism towards the country's pharmaceutical and...

2014-05-12 23:11:15

polyDNA’s newest survey for the month of May discovered that 36% of respondents with arthritis wanted to know if EBV is the cause of their disease. polyDNA reviews the literature on this topic and recommends Gene-Eden-VIR and Novirin against EBV, which is linked to arthritis. Rochester, NY (PRWEB) May 12, 2014 polyDNA’s latest survey revealed that 36% of respondents with arthritis wanted to know if EBV is the cause of their disease. One study found that “In latent and replicating...

2014-05-09 12:22:38

For more information about this release, please scroll to bottom. NEW YORK, May 9, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Zoetis Inc. (NYSE: ZTS), Aetna Inc. (NYSE: AET) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:...

2014-05-07 23:05:38

The U.S. Food and Drug Administration (FDA) approved the start of Phase II of required clinical studies for a new antibiotic, GSK944, developed by the Defense Threat Reduction Agency’s Chemical and Biological Technologies Department (DTRA CB) and its industry partner GlaxoSmithKline. Fort Belvoir, VA (PRWEB) May 07, 2014 The U.S. Food and Drug Administration (FDA) approved the start of Phase II of required clinical studies for a new antibiotic, GSK944, developed by the Defense Threat...

2014-05-07 16:30:16

LONDON, May 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:United Kingdom Pharmaceuticals and Healthcare Report Q2 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/united_kingdom_pharmaceuticals_healthcare_report_q2_2013.htmlIncludes 3 FREE quarterly updatesBMI View: The UK's health technology assessment and pricing/reimbursement decision making bodies arelooking to take an increasingly hard line when determining whether a new drug provides...

2014-05-06 08:33:10

Biotech Leadership with Significant Strategic and Financial Expertise SAN DIEGO, May 6, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, announced today the appointment of two new members to its Board of Directors. The new directors, Robert Baltera and Stuart Collinson, Ph.D., bring considerable biotech experience to the Arcturus Board. http://photos.prnewswire.com/prnvar/20130531/MM24393LOGO Robert "Bob" Baltera is a...

2014-04-30 20:23:46

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse(TM) Ellipta(®) (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK's first once-daily anticholinergic, a type of...

2014-04-30 08:33:26

LONDON, April 30, 2014 /PRNewswire/ -- SOURCE GlaxoSmithKline


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.